Non-hodgkin’s Lymphoma Pipeline constitutes 200+ key companies continuously working towards developing 220+ Non-hodgkin’s Lymphoma treatment therapies, analyzes DelveInsight.
Non-hodgkin’s Lymphoma Overview:
Non-Hodgkin Lymphoma (NHL) is a cancer of the lymphatic system, commonly affecting the lymph nodes. It encompasses a group of over 86 closely related cancers, collectively known as lymphoid neoplasms, as outlined in the 2016 World Health Organization classification. While these types share common traits, they differ in appearance, molecular features, growth patterns, impact on the body, and treatment responses.
NHL is the seventh most common cancer among adults in the United States, with its incidence nearly doubling between 1975 and 2013. Over 72,000 new cases were estimated in 2016. Symptoms often include swollen lymph nodes (usually painless), fever, night sweats, unexplained weight loss, and fatigue. However, these symptoms can also result from non-lymphoma conditions. Medical attention is recommended if symptoms persist for more than two weeks or are severe enough to disrupt daily life.
“Non-hodgkin’s Lymphoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-hodgkin’s Lymphoma Therapeutics Market.
Key Takeaways from the Non-hodgkin’s Lymphoma Pipeline Report
DelveInsight’s Non-hodgkin’s Lymphoma pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Non-hodgkin’s Lymphoma treatment.
In April 2025, Rituxan (rituximab) was approved for treating various blood cancers, autoimmune diseases, and inflammatory conditions, including follicular lymphoma (FL), non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), mature B-cell acute leukemia (B-AL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and pemphigus vulgaris (PV). RITUXAN HYCELA, a formulation combining rituximab with Halozyme’s hyaluronidase human ENHANZE technology, is approved for adults with previously untreated or relapsed/refractory FL, untreated DLBCL, and both untreated and treated CLL.
In March 2025, Lantern Pharma began dosing two participants in a Phase Ia/Ib clinical trial for LP-284, an experimental drug for relapsed or refractory NHL. LP-284 is a novel small molecule designed to eliminate cancer cells with mutations in DNA damage repair pathways through a synthetically lethal mechanism.
Key Non-hodgkin’s Lymphoma companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, and others are evaluating new drugs for Non-hodgkin’s Lymphoma to improve the treatment landscape.
Promising Non-hodgkin’s Lymphoma pipeline therapies in various stages of development include Mosunetuzumab, Tisagenlecleucel, Capivasertib, BI-1206, HMPL-760, and others.
Non-hodgkin’s Lymphoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Non-hodgkin’s Lymphoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-hodgkin’s Lymphoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-hodgkin’s Lymphoma market.
Download our free sample page report on Non-hodgkin’s Lymphoma pipeline insights
Non-hodgkin’s Lymphoma Emerging Drugs
Mosunetuzumab: Hoffmann-la Roche
Tisagenlecleucel: Novartis
Capivasertib: AstraZeneca
BI-1206: BioInvent
HMPL-760: Hutchmed
Non-hodgkin’s Lymphoma Companies
More than 200 prominent companies are actively working on developing therapies for Non-Hodgkin Lymphoma. Among them, Hoffmann-La Roche has drug candidates in the most advanced stage of development, Phase III.
DelveInsight’s report covers around 220+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Non-hodgkin’s Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Non-hodgkin’s Lymphoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Non-hodgkin’s Lymphoma Therapies and Key Companies: Non-hodgkin’s Lymphoma Clinical Trials and advancements
Non-hodgkin’s Lymphoma Pipeline Therapeutic Assessment
• Non-hodgkin’s Lymphoma Assessment by Product Type
• Non-hodgkin’s Lymphoma By Stage
• Non-hodgkin’s Lymphoma Assessment by Route of Administration
• Non-hodgkin’s Lymphoma Assessment by Molecule Type
Download Non-hodgkin’s Lymphoma Sample report to know in detail about the Non-hodgkin’s Lymphoma treatment market @ Non-hodgkin’s Lymphoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Non-hodgkin’s Lymphoma Current Treatment Patterns
4. Non-hodgkin’s Lymphoma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-hodgkin’s Lymphoma Late-Stage Products (Phase-III)
7. Non-hodgkin’s Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-hodgkin’s Lymphoma Discontinued Products
13. Non-hodgkin’s Lymphoma Product Profiles
14. Non-hodgkin’s Lymphoma Key Companies
15. Non-hodgkin’s Lymphoma Key Products
16. Dormant and Discontinued Products
17. Non-hodgkin’s Lymphoma Unmet Needs
18. Non-hodgkin’s Lymphoma Future Perspectives
19. Non-hodgkin’s Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Non-hodgkin’s Lymphoma Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
